Your Value & Dossier-Team
We are here for you
Dr. Willi Schnorpfeil holds a doctorate in economics and started his career at the AOK Bundesverband. His professional career has also included positions at AOK Hessen, Merck, Novo Nordisk and as a self-employed business consultant.
Dr. Schnorpfeil has more than 20 years of professional experience in the healthcare sector and has been advising companies strategically and operationally on all phases of the early benefit assessment according to AMNOG since 2011. As project manager of numerous AMNOG dossier projects in various indications, he has extensive experience in project management and the preparation of benefit dossiers. Dr. Schnorpfeil also has special expertise in the pricing of medicinal products and supports companies as a trainer in negotiations on the reimbursement amount.
Dr. Schnorpfeil has more than 20 years of professional experience in the healthcare sector and has been advising companies strategically and operationally on all phases of the early benefit assessment according to AMNOG since 2011. As project manager of numerous AMNOG dossier projects in various indications, he has extensive experience in project management and the preparation of benefit dossiers. Dr. Schnorpfeil also has special expertise in the pricing of medicinal products and supports companies as a trainer in negotiations on the reimbursement amount.
Dr. Angela Lammert is employed as Director HTA & Value Strategy at WS Value & Dossier. She advises pharmaceutical companies in market access for (innovative) medicinal products and medical devices. As Director in the field of AMNOG benefit dossiers, she has gained extensive experience through numerous projects in different indications such as oncology, neurology and ophthalmology. As Director, she is your direct contact for project management, preparation of the benefit dossier and strategic advice throughout the project.
Dr. Sandra Kiehlmeier holds a PhD in biology and has more than four years of experience in basic research in the field of molecular tumour biology. In her work as Medical Writer and Market Access Manager at WS Value & Dossier, she has overseen several projects in different indication areas, such as nephrology and neurology. Her tasks include conducting systematic literature searches as well as preparing consultation requests, cost analyses and benefit dossiers.
Dr. Hanna Klimek is a human biologist and spent 4 years conducting research on bacterial pathogens at the Institute for Hygiene at the Westphalian Wilhelms University in Münster. She studied in Denmark, Germany and France. Hanna is responsible for expanding our services to include new digital solutions in the pharmaceutical market. As Market Access Manager, she is also involved in market access of innovative medicinal products, reimbursement of medicinal products and training on hearings and price negotiations.
[in progress]
Michelle Woods is a biologist who contributed to basic research in cancer genetics at the Justus-Liebig University of Giessen for over six years. Her research focused mainly on the epigenetic regulation of tumor suppressor genes and the resulting influence on cell cycle-relevant signaling pathways. Her tasks include the creation of benefit dossiers and strategic advice on the AMNOG process. As a native speaker, she supports the Value & Dossier team with publications and international projects.
Christian Schneider studies industrial engineering with a focus on electrical engineering and information technology at TU Darmstadt. At Value & Dossier he works as a student assistant.
Belinda Blum studies biochemistry and is currently doing her Master of Science at JMU Würzburg, focussing on molecular oncology.
At Value & Dossier she works as a student assistant.
At Value & Dossier she works as a student assistant.
